ABBN.SW: $85.88 ▼ -0.22 (-0.26%)ASML.AS: $1,565.20 ▲ 4.40 (0.28%)ENR.DE: $161.54 ▼ -0.96 (-0.59%)GLEN.L: $537.60 ▲ 2.30 (0.43%)IFX.DE: $80.97 ▲ 0.41 (0.51%)NOKIA.HE: $12.16 ▲ 0.16 (1.33%)RIO.L: $7,295.00 ▲ 31.00 (0.43%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Co-Diagnostics, Inc.

CODX - NASDAQ

Identifiants & Marche

Ticker CODX
ISIN US1897631057
CIK 0001692415
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Medical - Devices

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.